Follow @chemandind


Health Examining the mechanisms of metastasis


Cancer cell metastasis usually involves several steps. The first is ‘local invasion’, in which cancer cells invade nearby normal tissue. This is followed by ‘intravasation’, where cancer cells invade and move through the walls of nearby lymph vessels or blood vessels. Next comes ‘circulation’, in which cancer cells move through the lymphatic system and the bloodstream to other parts of the body. Subsequent to this is ‘arrest and extravasation’, where cancer cells arrest, or stop moving, in small blood vessels called capillaries at a distant location. They then invade the walls of the capillaries and migrate into the surrounding tissue. ‘Proliferation’ occurs next, during which cancer cells multiply at the distant location to


everywhere in nature and has been isolated from untreated sewage, river and stagnant waters. Exposure to reovirus is common in humans, with half of all children by the age of 12 having been exposed and up to 100% testing positive by adulthood.


Reovirus actively reproduces itself within cells that possess a particular


2.6m


form small tumours known as micrometastases. Finally, a process called ‘angiogenesis’ occurs, in which micrometastases stimulate the growth of new blood vessels to obtain a blood supply. A blood supply is needed to obtain the oxygen and nutrients necessary for continued tumour growth. The ability of a cancer cell to metastasise


successfully depends on several factors. Not all cancer cells, by themselves, have the ability to metastasise. In addition, the non-cancerous cells at the original location may be able to block cancer cell metastasis. Furthermore, successfully reaching another location in the body does not guarantee that a metastatic tumour will form. Metastatic cancer cells can lie dormant or not


Number of people in the developed world that die every year of cancers which have metastasised


structural feature—known as an ‘activated Ras pathway’—that is shared by more than two-thirds of all cancer cells. Tumours bearing an activated Ras pathway can’t activate the anti-viral response mediated by the host cellular protein, PKR. Studies have shown that reovirus actively replicates in transformed cell lines with an active Ras signaling pathway, eventually killing the host cell and freeing the viral progeny that go on to infect and kill more tumour cells. When normal cells are infected with reovirus, the immune system can neutralise the virus. Approximately one-third of human cancers have activating mutations in the Ras gene itself. It is possible that more than two-thirds of cancer cells have an activated Ras signaling pathway because of activating mutations in genes upstream or downstream of Ras. Reolysin’s discovery dates to the early


1990s, when a University of Calgary researcher, Patrick Lee, was doing research on reoviruses. By the end of 1995, Lee and two colleagues, Matt Coffey and Jim Strong had the hypothesis that there might be a reovirus treatment for cancer. In 1998, they submitted the first patent on the use of the reovirus to treat cancer, and then assigning it to Oncolytics Biotech the following year in order to start development to turn the reovirus into a treatment. Three factors seem to contribute to the possibility that metastatic disease would be susceptible to treatment with Reolysin. First, reovirus appears to spread particularly easily to organs where metastasis is common, so a concentration of the drug can be built up in those regions of the body. Secondly, the cells that colonise a tumour to form the metastasis are believed to harbour genetic defects that provide a more accommodating environment for reovirus to colonise. Finally, a growing body of literature suggests Ras activation is required for metastasis to occur in the first place. Oncolytics believes its treatment is most effective in conjunction with chemotherapy; we are studying the effect of Reolysin in combination with the chemotherapy drugs carboplatin and paclitaxel. Reolysin is now being tested in a


randomised setting in head and neck cancer, non-small cell lung cancer, colorectal cancer, castration-resistant prostate cancer, drug-resistant ovarian cancer, breast and pancreatic cancer. All of these indications are associated with


grow at a distant site for many years before they begin to grow again, if at all.


When symptoms of metastatic cancer occur, the type and frequency of the symptoms will depend on the size and location of the metastasis. For example, cancer that spreads to the bone is likely to cause pain and can lead to bone fractures, while cancer that spreads to the brain can cause a variety of symptoms, including headaches, seizures, and unsteadiness. Sometimes, cancer is discovered only after a metastatic tumour causes symptoms. For example, a man whose prostate cancer has spread to his pelvis may have lower back pain before he experiences symptoms from the original tumour.


‘Reovirus actively reproduces itself within cells that possess a particular structural feature—known as an ‘activated Ras pathway’—that is shared by more than two-thirds of all cancer cells’


metastatic disease. Most recently, in May 2013,


Oncolytics reported preliminary data from a Phase 2 clinical trial showing that Reolysin, in combination with carboplatin and paclitaxel, reduced the size of tumours in patients with metastatic melanoma, a type of skin cancer. Three of 14 patients exhibited a partial response to the treatment, and an additional seven patients had stable disease for a disease control rate of 71.5%.


Virotherapy involves attacking cancer cells with viruses


C


So could a virus finally be the key to beating the mets? Future research studies will give us an


even clearer perspective on whether ours, or some other virus-based treatment like it, offers the most effective route forward. There may be new hope on the horizon for patients with metastatic disease, a hope coming from within the human body itself.


Brad Thompson is president and ceo of Oncolytics Biotech based in Calgary, Canada


Chemistry&Industry • November 2013 39


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64